Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598426 | 0.92 | ALOX5 (0.41) | ALOX5EPHX2ALDH1A1POLBL3MBTL1 | |
| SCHEMBL3430000 | 0.86 | TACR3 (0.40) | ALOX5EPHX2ITGB3ITGA2BTACR3 | |
| SCHEMBL1698890 | 0.86 | TACR3 (0.40) | ALOX5EPHX2ITGB3ITGA2BTACR3 | |
| SCHEMBL2772712 | 0.86 | TACR3 (0.40) | ALOX5EPHX2ITGB3ITGA2BTACR3 | |
| Dimethylformamide SCHEMBL27779363 | 0.85 | AKR1C3 (0.37) | ALOX5EPHX2AKR1C3ITGB3ITGA2B | |
| SCHEMBL27785354 | 0.83 | ALOX5 (0.46) | ALOX5EPHX2AKR1C3ITGB3ITGA2B | |
| SCHEMBL30014489 | 0.82 | ALDH1A1 (0.33) | ALOX5ITGB3ITGA2BTACR3ALDH1A1 | |
| SCHEMBL785724 | 0.82 | AKR1C3 (0.43) | AKR1C3ITGB3ITGA2BTYMPMEN1 | |
| SCHEMBL13734715 | 0.80 | HRH3 (0.42) | ALDH1A1POLB | |
| SCHEMBL17942545 | 0.79 | CPN1 (0.37) | ITGB3ITGA2BTACR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | claimed |
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | claimed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | claimed |
| CN-100528871-C | Benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | claimed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| EP-1456196-B1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| US-7371748-B2 | Benzothiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1636223-B1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | claimed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | claimed |
| CN-1296368-C | Benzothiophenes as adenosine receptor modulators | HOFFMANN LA ROCHE (CH) | 2007-01-24 | — | — | CN | claimed |
| WO-2005035541-A1 | SILICON COMPOUNDS AND THEIR USE | AMEDIS PHARMACEUTICALS LTD. (GB) | 2005-04-21 | — | — | WO | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| CN-1602309-A | Benzothiophenes as adenosine receptor modulators | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | claimed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| WO-2004113353-A1 | SILICON-COMPRISING AMINOTHIAZOLE DERIVATIVES AS CDK INHIBITORS | AMEDIS PHARMACEUTICALS LTD. (GB) | 2004-12-29 | — | — | WO | claimed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | claimed |
| EP-1456196-A1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-6730670-B2 | FOR PROPHYLAXIS OF ILLNESSES BASED ON MODULATION OF ADENOSINE SYSTEM, SUCH AS ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, NEUROPROTECTION, SCHIZOPHRENIA, ANXIETY, PAIN, RESPIRATION DEFICITS, DEPRESSION, DRUG ADDICTION | HOFFMANN-LA ROCHE INC. | 2004-05-04 | — | — | US | claimed |
| US-20030149030-A1 | 7-phenyl-benzo [b] thiophen amide derivatives | HOFFMANN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003053954-A1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | ALOX5 2688/4885EPHX2 3330/4885AKR1C3 2731/4885 |
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | ALOX5 2599/4885EPHX2 1902/4885AKR1C3 2042/4885 |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | ALOX5 559/4885EPHX2 2067/4885AKR1C3 1258/4885 |
| US-20030149030-A1 | 7-phenyl-benzo [b] thiophen amide derivatives | ADORA2A, ADORA2B, ADORA1 | ALOX5 1142/4885EPHX2 2416/4885AKR1C3 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.